Leyland-Jones, Brian
McGill University · European Institute of Oncology
3 papers on CoChatORCID 0000-0003-2434-0774
Most cited papers
- Verified
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 11,500
- Verified
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine
HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies
Cited by 5,084
- Verified
Echinomycin: The first bifunctional intercalating agent in clinical trials
Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B. (1985) · Investigational New Drugs
Cancer therapeutics and mechanismsBioactive Compounds and Antitumor Agents
Cited by 61
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free